Eucalyptus is a technology company.
Eucalyptus has raised $102.0M across 4 funding rounds.
Key people at Eucalyptus.
Eucalyptus has raised $102.0M in total across 4 funding rounds.
Key people at Eucalyptus.
Eucalyptus has raised $102.0M in total across 4 funding rounds.
Eucalyptus's investors include Andreessen Horowitz, Bond, Rainfall Ventures, Stellar Capital, Blackbird Ventures Australia, Craft Ventures, Great Oaks Venture Capital, GSV Acceleration, Maveron, NewView Capital, Treble Capital, Nils Johnson.
Eucalyptus is a healthcare technology company founded in 2019 that builds and operates a vertically integrated telehealth platform delivering personalized digital healthcare experiences for patients. It serves over 200,000 patients primarily in Australia, the UK, Germany, and Japan through multiple specialized brands addressing obesity (Juniper), men’s health (Pilot), women’s fertility and contraception (Kin), skincare (Software), and sexual wellness (Normal). Eucalyptus’s platform connects telehealth consultations, pharmacy delivery, and ongoing care to solve chronic and demographic-specific health challenges, enabling better patient outcomes and higher engagement across its services[1][2][3].
The company’s mission is to fix the broken healthcare system by providing accessible, high-quality care that addresses rising chronic conditions like obesity and diabetes through a scalable digital model. Eucalyptus has demonstrated strong growth momentum with over one million consultations facilitated, significant weight loss outcomes for patients, and cost savings to healthcare systems. Its vertically integrated platform allows rapid launch and scaling of new brands and features, driving customer retention and expanding usage over time[2][6].
---
Eucalyptus was founded in 2019 in Sydney, Australia, by a team focused on transforming healthcare delivery through technology. The idea emerged from recognizing the inefficiencies and access barriers in traditional healthcare, especially for chronic and demographic-specific conditions. Early traction came from launching multiple digital health brands that leveraged a shared technology platform, enabling efficient operations and rapid expansion. This foundation allowed Eucalyptus to become Australia’s largest vertically integrated telehealth platform within a few years, serving hundreds of thousands of patients and expanding internationally[1][2][3].
---
---
Eucalyptus rides the global trend toward digital transformation in healthcare, particularly telehealth and personalized medicine. The timing is critical as chronic diseases like obesity and diabetes rise worldwide, and healthcare systems face pressure to improve access, reduce costs, and enhance patient engagement. Eucalyptus’s vertically integrated model addresses these market forces by combining technology, clinical care, and pharmacy services in one platform, enabling proactive chronic disease management and behavioral health support. This approach influences the broader ecosystem by setting a new standard for scalable, patient-centered digital healthcare delivery[2][6].
---
Looking ahead, Eucalyptus is poised for exponential growth by expanding its portfolio to address more complex chronic conditions and new demographic segments globally. Trends such as increasing telehealth adoption, demand for personalized care, and digital health integration will shape its journey. The company’s scalable platform and strong clinical foundation position it to deepen its influence on healthcare delivery models, potentially becoming a global leader in condition-specific digital health ecosystems. Continued innovation in technology and care pathways will be key to sustaining momentum and expanding impact[2][6].
Eucalyptus exemplifies how technology can fix systemic healthcare challenges by delivering accessible, effective, and personalized care that lasts a lifetime.
Eucalyptus has raised $102.0M across 4 funding rounds. Most recently, it raised $33.0M Series C in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $33.0M Series C | Andreessen Horowitz, Bond, Rainfall Ventures, Stellar Capital | |
| Jan 1, 2022 | $42.0M Series C | Andreessen Horowitz, Blackbird Ventures Australia, Bond, Craft Ventures, Great Oaks Venture Capital, GSV Acceleration, Maveron, NewView Capital, Rainfall Ventures, Stellar Capital, Treble Capital, Nils Johnson, Steve Chen | |
| Jul 1, 2021 | $22.0M Series B | Blackbird Ventures Australia, Bond, Craft Ventures, Great Oaks Venture Capital, GSV Acceleration, Maveron, NewView Capital, Treble Capital, Nils Johnson, Steve Chen | |
| May 1, 2020 | $5.0M Series A | Blackbird Ventures Australia, Treble Capital |
